Patents Assigned to Almac Discovery Limited
  • 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19)
    Patent number: 11807646
    Abstract: Inhibitors of ubiquitin specific protease 19 (USP19) of Formula (I) are provided, together with pharmaceutical compositions comprising said inhibitors, and methods of use thereof. The compounds can be used in in the treatment of muscular atrophy, obesity, insulin resistance or type II diabetes or in reducing the loss of muscle mass.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: November 7, 2023
    Assignee: ALMAC DISCOVERY LIMITED
    Inventors: James Samuel Shane Rountree, Steven Kristopher Whitehead, Adam Piotr Treder, Lauren Emma Proctor, Steven David Shepherd, Frank Burkamp, Joana Rita Castro Costa, Colin O'Dowd, Timothy Harrison
  • ROR1-SPECIFIC ANTIGEN BINDING MOLECULES
    Publication number: 20230203155
    Abstract: The present invention relates to receptor tyrosine kinase-like orphan receptor 1 (ROR1) specific antigen binding molecules and associated fusion proteins and conjugates. In a further aspect, the present invention relates to conjugated immunoglobulin-like shark variable novel antigen receptors (VNARs).
    Type: Application
    Filed: December 21, 2018
    Publication date: June 29, 2023
    Applicant: ALMAC DISCOVERY LIMITED
    Inventors: Estelle Grace McLean, Paul Richard Trumper, Jennifer Thom, Timothy Harrison, Graham John Cotton, Caroline Barelle, Andrew Porter, Marina Kovaleva
  • BI-SPECIFIC BINDING MOLECULES
    Publication number: 20210317204
    Abstract: The present invention relates to bi-specific antigen binding molecules and associated fusion proteins and conjugates. In particular, the present invention relates to bi-specific antigen binding molecules with specificity for both receptor tyrosine kinase-like orphan receptor 1 (ROR1) and epidermal growth factor receptor (EGFR) and associated fusion proteins and conjugates. In a further aspect, the present invention relates to conjugated immunoglobulin-like shark variable novel antigen receptors (VNARs).
    Type: Application
    Filed: December 21, 2018
    Publication date: October 14, 2021
    Applicant: ALMAC DISCOVERY LIMITED
    Inventors: Estelle Grace McLean, Paul Richard Trumper, Jennifer Thom, Timothy Harrison, Graham John Cotton, Chiara Saladino, Caroline Barelle, Andrew Porter, Marina Kovaleva
  • Pharmaceutical compounds
    Patent number: 11053213
    Abstract: The present invention relates to compounds of Formula (I) that are useful as inhibitors of the activity of the ubiquitin specific protease USP19. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in therapy.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: July 6, 2021
    Assignee: ALMAC DISCOVERY LIMITED
    Inventors: Peter Hewitt, Mary Melissa McFarland, James Samuel Shane Rountree, Frank Burkamp, Christina Bell, Lauren Proctor, Matthew Duncan Helm, Colin O'Dowd, Timothy Harrison
  • Wee-1 inhibiting pyrazolopyrimidinone compounds
    Patent number: 10766902
    Abstract: The present invention relates to pyrazolopyrimidinone derivatives, such as those of Formula (I), that are useful as inhibitors of the activity of Wee-1 kinase.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: September 8, 2020
    Assignee: ALMAC DISCOVERY LIMITED
    Inventors: Frank Burkamp, James Samuel Shane Rountree, Adam Piotr Treder
  • Piperidine derivatives as inhibitors of ubiquitin specific protease 7
    Patent number: 10766903
    Abstract: The present invention concerns the identification of inhibitors of ubiquitin specific protease 7 (USP7), and methods of use thereof.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: September 8, 2020
    Assignee: ALMAC DISCOVERY LIMITED
    Inventors: Colin O'Dowd, Tim Harrison, Peter Hewitt, Shane Rountree, Miel Hugues, Frank Burkamp, Linda Duncan Jordan, Matthew Helm, Fabio Broccatelli, James John Crawford, Lewis Gazzard, Ingrid Wertz, Wendy Lee
  • FKBP-L polypeptides and uses in angiogenesis-mediated disorders
    Patent number: 10577406
    Abstract: Disclosed are methods and compositions that employ FKBP-L polypeptides for modulating angiogenesis and/or tumor metastasis. The FKBP-L polypeptides may be used for the treatment of disorders mediated by angiogenesis such as cancer.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: March 3, 2020
    Assignee: ALMAC DISCOVERY LIMITED
    Inventors: Tracy Robson, Andrea Valentine, Martin Gerard O'Rourke, David Hirst
  • TREATMENT OF OCULAR DISEASE
    Publication number: 20190231847
    Abstract: A treatment of ocular disease, and more specifically disorders of the cornea, using the polypeptide FKBP-L and peptide fragments thereof is provided.
    Type: Application
    Filed: June 21, 2017
    Publication date: August 1, 2019
    Applicant: ALMAC DISCOVERY LIMITED
    Inventor: Tara MOORE
  • PHARMACEUTICAL COMPOUNDS
    Publication number: 20190233394
    Abstract: The present invention relates to compounds of Formula (I) that are useful as inhibitors of the activity of the ubiquitin specific protease USP19. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in therapy.
    Type: Application
    Filed: July 26, 2017
    Publication date: August 1, 2019
    Applicant: Almac Discovery Limited
    Inventors: Peter HEWITT, Mary Melissa MCFARLAND, James Samuel Shane ROUNTREE, Frank BURKAMP, Christina BELL, Lauren PROCTOR, Matthew Duncan HELM, Colin O'DOWD, Timothy HARRISON
  • Substituted pyrido[4,3-d]pyrimidines as Wee-1 inhibitors
    Patent number: 9714244
    Abstract: The present invention relates to compounds of formula (I) that are useful as inhibitors of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in the treatment of cancer and methods of treating cancer.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: July 25, 2017
    Assignee: ALMAC DISCOVERY LIMITED
    Inventors: Colin Roderick O'Dowd, James Samuel Shane Rountree, Frank Burkamp, Andrew John Wilkinson
  • FKBP-L AND USES THEREOF
    Publication number: 20160340401
    Abstract: Disclosed are methods and compositions that employ FKBP-L polypeptides for modulating angiogenesis and/or tumor metastasis. The FKBP-L polypeptides may be used for the treatment of disorders mediated by angiogenesis such as cancer.
    Type: Application
    Filed: May 31, 2016
    Publication date: November 24, 2016
    Applicant: ALMAC DISCOVERY LIMITED
    Inventors: Tracy Robson, Andrea Valentine, Martin Gerard O'Rourke, David Hirst
  • FKBP-L AND USES THEREOF
    Publication number: 20160340402
    Abstract: Disclosed are methods and compositions that employ FKBP-L polypeptides for modulating angiogenesis and/or tumor metastasis. The FKBP-L polypeptides may be used for the treatment of disorders mediated by angiogenesis such as cancer.
    Type: Application
    Filed: May 31, 2016
    Publication date: November 24, 2016
    Applicant: ALMAC DISCOVERY LIMITED
    Inventors: Tracy Robson, Andrea Valentine, Martin Gerard O'Rourke, David Hirst
  • FKBP-L and uses thereof
    Patent number: 9381228
    Abstract: Disclosed are methods and compositions that employ FKBP-L polypeptides for modulating angiogenesis and/or tumor metastasis. The FKBP-L polypeptides may be used for the treatment of disorders mediated by angiogenesis such as cancer.
    Type: Grant
    Filed: June 8, 2007
    Date of Patent: July 5, 2016
    Assignee: ALMAC DISCOVERY LIMITED
    Inventors: Tracy Robson, Andrea Valentine, Martin Gerard O'Rourke, David Hirst
  • Inhibitors of AKT activity
    Patent number: 9221838
    Abstract: The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: December 29, 2015
    Assignee: ALMAC DISCOVERY LIMITED
    Inventors: Lixin Zhang, Graham Peter Trevitt, Hugues Miel, Frank Burkamp, Timothy Harrison, Andrew John Wilkinson, Charles-Henry Fabritius
  • AKT inhibitor compounds for treatment of cancer
    Patent number: 9156853
    Abstract: The present invention relates to compounds that are useful as inhibitors of the activity of one or more isoforms of the serine/threonine kinase, AKT. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in the treatment of cancer and methods of treating cancer.
    Type: Grant
    Filed: March 25, 2013
    Date of Patent: October 13, 2015
    Assignee: ALMAC DISCOVERY LIMITED
    Inventors: Timothy Harrison, Colin O'Dowd, Steven Shepherd, Graham Trevitt, Lixin Zhang, Frank Burkamp
  • Pharmaceutical compounds
    Patent number: 8546376
    Abstract: The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.
    Type: Grant
    Filed: September 17, 2010
    Date of Patent: October 1, 2013
    Assignee: Almac Discovery Limited
    Inventors: Mark Peter Bell, Timothy Harrison, Sumita Bhattacharyya, James Samuel Shane Rountree, Frank Burkamp, Stephen Price, Calum MacLeod, Richard Leonard Elliott, Phillip Smith, Toby Jonathan Blench, Colin Roderick O'Dowd, Lixin Zhang, Graham Peter Trevitt, Hazel Joan Dyke
  • INHIBITORS OF AKT ACTIVITY
    Publication number: 20130116243
    Abstract: The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.
    Type: Application
    Filed: December 23, 2010
    Publication date: May 9, 2013
    Applicant: ALMAC DISCOVERY LIMITED
    Inventors: Lixin Zhang, Graham Peter Trevitt, Hugues Miel, Frank Burkamp, Timothy Harrison, Andrew John Wilkinson, Charles-Henry Fabritius
  • AKT / PKB INHIBITORS
    Publication number: 20120309739
    Abstract: The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.
    Type: Application
    Filed: November 3, 2010
    Publication date: December 6, 2012
    Applicant: ALMAC DISCOVERY LIMITED
    Inventors: Mark Peter Bell, Colin Roderick O'Dowd, James Samuel Shane Rountree, Graham Peter Trevitt, Timothy Harrison, Mary Melissa McFarland
  • PHARMACEUTICAL COMPOUNDS
    Publication number: 20120238541
    Abstract: The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.
    Type: Application
    Filed: September 17, 2010
    Publication date: September 20, 2012
    Applicant: Almac Discovery Limited
    Inventors: Mark Peter Bell, Timothy Harrison, Sumita Bhattacharyya, James Samuel Shane Rountree, Frank Burkamp, Stephen Price, Calum MacLeod, Richard Leonard Elliott, Phillip Smith, Toby Jonathan Blench, Colin Roderick O'Dowd, Lixin Zhang, Graham Peter Trevitt, Hazel Joan Dyke